Herantis Pharma Oyj
HRTIS.HEDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Lymfactin® (1x10E11 vp)
Secondary Lymphedema
Cerebral Dopamine Neurotrophic Factor
Parkinson Disease
cis-UCA ophthalmic solution 1.0%
Dry Eye Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lymfactin® (1x10E11 vp) | Phase 2 | Secondary Lymphedema | - | - |
Cerebral Dopamine Neurotrophic Factor | Phase 2 | Parkinson Disease | - | - |
cis-UCA ophthalmic solution 1.0% | Phase 2 | Dry Eye Syndrome | - | - |
Frequently asked questions
What is in Herantis Pharma Oyj's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Herantis Pharma Oyj's (HRTIS.HE) pipeline across Phase 2. Its lead program is Lymfactin® (1x10E11 vp) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Herantis Pharma Oyj's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Herantis Pharma Oyj (HRTIS.HE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HRTIS.HE biotech catalysts?→
Add HRTIS.HE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Herantis Pharma Oyj's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.